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abStract
background The clustering of metabolic and cardiovascular risk factors is known 
as the metabolic syndrome (MetS). The risk of having MetS is strongly associated 
with increased adiposity and can be further modified by smoking. Apolipoproteins 
(apo) associated with low density lipoprotein cholesterol (LDL-C) and high-density 
lipoprotein cholesterol (HDL-C) may be altered in MetS. This study aimed to examine 
the association between smoking and the following parameters: MetS and its com-
ponents, levels of apolipoproteins and estimated lipoprotein particle size, separately 
for men and women, and in different body mass index (BMI) classes.
methods We included 24,389 men and 35,078 women, aged between 18 and 80 years 
who participated in the LifeLines Cohort Study between December 2006 and 
January 2012; 5,685 men and 6,989 women were current smokers. Participants were 
categorized into three different BMI classes (BMI <25; BMI 25-29.9; BMI ≥30 kg/m2). 
MetS was defined according to the NCEP:ATPIII criteria. Blood pressure, anthropo-
metric and lipid measurements were rigorously standardized, and the large sample 
size enabled a powerful estimate of quantitative changes. The association between 
smoking and the individual MetS components, and apoA1 and apoB, was tested 
with linear regression. Logistic regression was used to examine the effect of smoking 
and daily tobacco smoked on risk of having MetS. All models were age adjusted and 
stratified by gender and BMI class.
results Prevalence of MetS increased with higher BMI levels. 64% of obese men and 
42% of obese women had MetS. Current smoking was associated with a higher risk 
of MetS in both genders and all BMI classes (odds ratio 1.7-2.4 for men, 1.8-2.3 for 
women, all Ps<0.001). Current smokers had lower levels of HDL cholesterol and 
apoA1, higher levels of triglycerides and apoB, and higher waist circumference 
than non-smokers (all P<0.001). Smoking had no consistent association with blood 
pressure or fasting blood glucose. In all 5 BMI classes, we found a dose-dependent 
association of daily tobacco consumption with MetS prevalence as well as with lower 
levels of HDL cholesterol, higher triglyceride levels and lower ratios of HDL choles-
terol/apoA1 and - only in those with BMI<30 – LDL cholesterol/apoB (all P<0.001).
conclusions Smoking is associated with an increased prevalence of MetS, independent 
of gender and BMI class. This increased risk is mainly related to lower HDL cholesterol, 
and higher triglycerides and waist circumference. In addition, smoking was associ-
ated with unfavourable changes in apoA1 and apoB, and in lipoprotein particle size.
Keywords Metabolic Syndrome, Smoking, HDL Cholesterol, Apolipoproteins, Triglycer-
ides, Obesity, Cross-sectional.
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iNtroductioN
Metabolic syndrome (MetS) is a combination of unfavorable health factors including 
abdominal obesity, dyslipidemia, hypertension and glucose intolerance [1,2] and is 
strongly associated with increased risk of cardiovascular disease (CVD) and type 2 dia-
betes [1,2]. One of the key drivers in the development of MetS is obesity [3]. In recent 
years, the global prevalence of obesity has increased at alarming rates, and MetS and 
its consequences have become a major public health burden [4,5]. This rise in MetS 
prevalence has also been observed in non-obese individuals [6-8] and there is strong 
evidence that the increase is mainly the result of unfavorable lifestyle changes, such as 
inactivity and poor nutrition [9].
Smoking has also been implicated as a risk factor for MetS. Earlier studies have 
suggested that overall tobacco use is associated with an increased risk of MetS [10,11], 
most likely due to its effects on waist circumference, blood lipids and blood pressure 
[10,12,13]. Such metabolic abnormalities may also be modulated by a direct negative 
effect of smoking on insulin resistance [12]. The degree to which smoking modulates 
the risk of developing obesity-related MetS still remains unclear, however. While the as-
sociation between smoking, metabolic disturbances and the presence of MetS has been 
firmly established in obese individuals [7,8], with a similar trend observed in normal 
weight individuals [7], these findings could not be confirmed by others [8,14].
Alterations in the size and composition of low-density lipoprotein (LDL) particles 
and high-density lipoprotein (HDL) particles have been associated with metabolic 
syndrome [15], and are known to be related to CVD risk [16]. Individuals with altered 
HDL cholesterol (HDL-C) and triglyceride levels, two components of MetS, are more 
likely to also have unfavorable changes in the levels of apolipoproteins (apo) A1 and 
B, the apolipoproteins associated with HDL-C and LDL-C, as well as altered size and 
composition of these lipoprotein particles [17]. Although small-scale studies have sug-
gested that smoking may influence the levels of apolipoproteins and the composition 
of lipoproteins [18-20], the extent to which this is associated with prevalent BMI and the 
risk of MetS is largely unknown. In addition, the latter studies have been published over 
two decades ago, and since then improved standardization has made apolipoprotein 
assays more reliable and reproducible [21,22].
The aim of the present study was to examine the association between smoking and 
the individual components of MetS in normal weight, overweight and obese subjects, 
in a very large population-based cohort study [23]. We also assessed the relationship 
between smoking and apolipoprotein levels, and between smoking and lipoprotein 
particle size, using the HDL-C/apoA1 and LDL-C/apoB ratios as a proxy.
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mEthodS
Study design and subjects
The LifeLines Cohort Study is a multidisciplinary prospective population-based cohort 
study that examines the health and health-related behaviors of participants living in 
the northeast of The Netherlands [23]. It employs a wide range of procedures to assess 
the biomedical, sociodemographic, behavioral, physical and psychological factors 
that contribute to the health and disease of the general population, with a focus on 
multimorbidity. All participants filled in an extensive questionnaire about health-
related items and lifestyle and underwent a clinical examination that included standard 
anthropometric and blood pressure measurements performed by trained technicians 
and collection of biological samples. All participants provided written informed consent 
before participating in the study. The study protocol was approved by the medical ethi-
cal review committee of the University Medical Center Groningen.
For this cross-sectional study we included subjects of Western European origin 
(according to self-reported information in the questionnaire), aged between 18 and 80 
years who participated in the LifeLines Cohort Study between December 2006 and Janu-
ary 2012. Individuals who had missing data on BMI (n = 21), or on the variables needed 
to define MetS (n = 2,044), or whose questionnaires were incomplete with regard to 
smoking behavior (n = 2,202) were excluded from analysis. A total of 59,467 individuals 
were available for the current analysis.
clinical examination
The anthropometric measurements height, weight, waist and hip circumference, and 
blood pressure were conducted by trained technicians using a standardized protocol. 
Body weight was measured without shoes with 0.1 kg precision. Height, waist and hip 
circumference were measured to the nearest 0.5 cm. Waist circumference was measured 
in standing position with a tape measure all around the body, at the level midway 
between the lower rib margin and the iliac crest. Systolic and diastolic blood pressures 
were measured every minute for a period of 10 minutes using an automated Dinamap 
Monitor (GE Healthcare, Freiburg, Germany). The size of the cuff was chosen according 
to the arm circumference. The average of the last three readings was recorded for each 
blood pressure parameter.
biochemical measurements
At a second visit, blood was collected in the fasting state, between 8.00 and 10.00 a.m. 
The blood samples were transported under temperature-controlled conditions (at 
room temperature or at 4°C, depending on the sample requirements) to the LifeLines 
central laboratory facility. All measurements were performed the same day. Total and 
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HDL cholesterol were measured using an enzymatic colorimetric method, triglycerides 
using a colorimetric UV method, and LDL-C using an enzymatic method, all on a Roche 
Modular P chemistry analyzer (Roche, Basel, Switzerland). Apolipoprotein A1 (apoA1) 
and apolipoprotein B (apoB) were measured by nephelometry (Siemens, Munich, Ger-
many). Fasting blood glucose was measured using a hexokinase method.
assessment of metabolic syndrome and lipoprotein particle size
BMI was calculated as weight (kg) divided by height squared (m2). We classified the 
subjects into three BMI categories: normal weight (BMI <25.0), overweight (BMI 25.0 
to 30) or obese (BMI ≥30). Individuals with a BMI <30 were considered to have MetS if 
they satisfied at least three of the five criteria named in the revised National Cholesterol 
Education Program’s Adult Treatment Panel III (NCEP:ATPIII, Table 1) [2]. Individuals with 
a BMI ≥30 were considered to have MetS if they satisfied at least two of the four MetS cri-
teria (excluding waist circumference since a BMI ≥30 overrules the waist circumference 
criterion). The HDL-C/apoA1 ratio and LDL-C/apoB ratio were calculated to estimate 
differences in HDL-C and LDL-C particle size.
data description
Diagnosis of earlier myocardial infarction or hypertension was self-reported, as was the 
use of medication. Diagnosis of diabetes mellitus was based either on self-report, or 
on the finding of a fasting blood glucose >7.0 mmol/l. Information about smoking was 
collected from the self-administered questionnaires. Respondents were asked whether 
table 1. The revised National Cholesterol Education Program’s Adult Treatment Panel III criteria (NCEP:ATP 
III): for a person to be defined as having metabolic syndrome (MetS) they must satisfy at least three of the 
five criteria below. a
Criteria Details
Raised blood pressure Systolic blood pressure (SBP) ≥130 mmHg or
diastolic blood pressure (DBP) ≥85 mmHg or
use of blood pressure-lowering medication
Elevated glucose level Fasting blood glucose ≥5.6 mmol/l or use of
blood glucose-lowering medication or
diagnosis of type 2 diabetes
Decreased high-density lipoprotein cholesterol <1.03 mmol/l in men or <1.30 mmol/l in
women or lipid-lowering medical treatment
Elevated triglycerides ≥1.70 mmol/l or medication for elevated
triglycerides
Abdominal obesity (increased waist circumference) ≥102 cm in men or ≥88 cm in women
a If body mass index (BMI) is ≥30 kg/m2, abdominal obesity can be assumed and waist circumference is 
not included as a criterion. A person with BMI ≥30 must satisfy at least two of the four other criteria to be 
defined as having MetS.
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they smoked; whether they had smoked during the last month and whether they had 
ever smoked for an entire year; whether they had stopped smoking; which type of 
tobacco they currently smoked (cigarette, cigarillo, cigar, pipe tobacco or a mixture of 
different kinds); and the amount smoked (number of cigarettes smoked per day and/or 
grams tobacco per week, in the case of pipe smokers).
The subjects were classified according to smoking status as non-smoker, former 
smoker or current smoker. Subjects were defined as a non-smoker if they had not smoked 
during the last month and had also never smoked for longer than a year. Former smok-
ers were those who had not smoked during the last month but reported to have smoked 
for longer than a year and had stopped smoking. Current smokers were subjects who 
reported to have smoked during the last month or those who reported to have smoked 
for longer than a year and had not stopped smoking. Estimation of current smokers’ total 
tobacco use and their classification into light, moderate and heavy smokers were based 
on the following quantities: one cigarette = 1 g tobacco, one cigarillo = 3 g tobacco and 
one cigar = 5 g tobacco. Light smoking was defined as 10 g/day or less, moderate as 11 
to 20 g/day and heavy as more than 20 g/day.
Statistical methods
All analyses were conducted using IBM SPSS Statistics version 20 (IBM Corporation, 
Armonk, NY, USA). Data are presented as means ± SD, or geometric mean and interquar-
tile range when they were not normally distributed. For comparisons between groups, 
analysis of variance was used where appropriate. Linear regression was used to examine 
the associations between smoking and the five components of MetS as well as between 
smoking and the apolipoprotein levels and the HDL-C/apoA1 and LDL-C/apoB ratios. 
Logistic regression was used to examine the effect of smoking and daily tobacco use on 
the risk of having MetS. This approach generated odds ratios that predicted the odds of 
having MetS for the different smoking statuses and different amounts of tobacco usage. 
Since distributions for triglyceride and fasting blood glucose were right skewed, before 
analysis we log-transformed (natural log) values to approximate normal distribution. All 
analyses were stratified for sex and BMI class, and were additionally adjusted for age.
We applied a Bonferroni correction to account for the number of independent tests. 
A P value of ≤0.001 (0.05/48) was regarded as significant, given 48 independent tests (6 
statistical models × 8 traits). Since the analyses were performed separately for men and 
women, and also for each BMI class, we used six models. The eight traits were as follows: 
(1) systolic and diastolic blood pressure or hypertension; (2) fasting glucose level; (3) 
HDL-C level; (4) triglyceride level; (5) waist circumference; (6) apoA1 and apoB; (7) HDL-
C/apoA1 and LDL-C/apoB ratios; and (8) MetS.
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rESultS
The baseline characteristics of the participants are summarized in Table 2. Obesity preva-
lence was 14.4% in men and 16.1% in women. Subjects who were overweight or obese 
were slightly older than those with normal weight. Among normal weight men, 24.6% 
were current smokers, while 22.3% of the overweight and 23.1% of the obese were cur-
rent smokers. Among normal weight women, 21.1% were current smokers, while 19.6% 
of the overweight and 16.8% of the obese were current smokers. For both sexes, systolic 
and diastolic blood pressure, serum triglycerides, blood glucose, LDL-C and apoB, as 
well as the percentage of subjects with type 2 diabetes, showed a consistent increase 
with increasing BMI. The same trend was observed for the percentage of subjects using 
medication to control elevated blood pressure, triglycerides or blood glucose. HDL-C 
and apoA1 levels, as well as the HDL-C/apoA1 ratio, showed a consistent decrease with 
increasing BMI. While in subjects with BMI <25 the overall prevalence of MetS was 3.6% 
in men and 2.4% in women, in the overweight this figure was 21.6% in men and 16.0% 
in women, rising to 64.3% of obese men and 41.5% of obese women.
For both sexes, former smokers were older and had higher levels of BMI, blood pres-
sure, LDL-C, total cholesterol, waist circumference and glucose and were more frequently 
diagnosed with type 2 diabetes than non-smokers and current smokers (Table 3). Cur-
rent smokers had the lowest levels of HDL-C and apoA1, the lowest HDL-C/apoA1 ratio, 
and the highest levels of triglycerides and, in women, apoB.
The percentage of subjects with MetS according to smoking status and daily tobacco 
consumption are shown in Figure 1. In both men and women, prevalence of MetS was 
greater in current smokers within each BMI group. In men, smoking was associated with 
higher MetS prevalence, although in the normal weight and obese men there was no 
difference between moderate and heavy smokers. In women there was a more pro-
nounced dosage effect, that is, the percentage of individuals with MetS increased with 
an increase in the amount of tobacco smoked. Former smokers had a higher prevalence 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































For all BMI classes and smoking statuses, the percentage of subjects with high blood 
pressure, elevated blood glucose and elevated triglyceride levels was higher in men than 
in women, whereas women were more likely than men to have a higher waist circumfer-
ence (Figure 2). In both sexes, increasing amounts of tobacco smoked were strongly 
associated with an increase in the number of individuals showing abnormal HDL-C and 
triglyceride levels. The amount of tobacco smoked was also associated with increased 
waist circumference, especially in overweight individuals. There were no consistent ef-
fects of the amount of tobacco smoked on blood pressure and blood glucose, nor did 
the amount of tobacco smoked influence blood pressure levels following correction for 




















≥ 20 g daily
Women
figure 1. Prevalence of metabolic syndrome in non-smokers, former smokers and current smokers.
Note that in all body mass index (BMI) classes prevalence of metabolic syndrome was higher in former 
smokers than in non-smokers, and that a dose-response relationship was found between prevalence of 
metabolic syndrome and amount of smoking, especially in women.







































































































figure 2. Prevalence of the individual components of metabolic syndrome according to sex (left panel: 
men; right panel: women) and body mass index (BMI) class.
Top: BMI <25 kg/m2; middle; BMI 25 to 30 kg/m2; bottom: BMI ≥30 kg/m2. For all BMI classes, more men met 
the criteria for high blood pressure, elevated blood glucose and elevated triglyceride levels than did wom-
en, while women more frequently met the criteria for high waist circumference. Prevalence of high-density 
lipoprotein (HDL) abnormalities was not different between men and women. Higher tobacco consump-
tion was particularly associated with abnormalities in HDL cholesterol and triglycerides, and to a lesser 
extent with abnormal waist circumference. BP, blood pressure; glucose, blood glucose; HDL-C, high-density 
lipoprotein-cholesterol; TG, triglycerides; waist, waist circumference.
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Table 4 presents the associations between smoking and individual MetS components 
and between smoking and apolipoprotein levels and ratios, for the three different BMI 
classes, stratified by sex. There was a significant fall of HDL-C levels associated with 
greater amount of tobacco smoked in both sexes and all three BMI classes (P <0.001). In 
addition, the HDL-C/apoA1 ratio was significantly lower for higher amount of tobacco 
smoked in all BMI classes, and the LDL-C/apoB ratio for the lowest BMI classes (P <0.001). 
Former smokers had similar HDL-C levels to those of non-smokers. In all BMI classes, 
there was a consistent positive association between tobacco use and triglyceride levels 
(all P values <0.001). In all tobacco use groups, waist circumference was higher than that 
of non-smokers, independent of sex and BMI class, except for obese male light smokers. 
In obese female smokers we observed the largest rise in waist circumference: from 2.2 
cm in moderate smokers to 6.4 cm in heavy smokers (both P <0.001). Moderate and 
heavy smoking was not associated with any strong changes in fasting blood glucose 
level.
The age-corrected odds ratios for having MetS, for men and women separately, in 
the three BMI classes, are depicted in Figure 3. In all BMI classes there was a significant 
rise in odds ratio with increasing amount of tobacco smoked. This trend was stronger in 
women than in men (P <0.001).
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figure 3. Age-corrected odds ratios for having metabolic syndrome, in men (left panels) and women 
(right panels) according to body mass index (BMI) class.
N, non-smokers; E, former smokers; C1, smokers of 0 to 10 g tobacco daily; C2, smokers of 10 to 20 g daily; 
C3, smokers of ≥20 g daily. Top: BMI <25; middle: BMI 25 to 30; bottom: BMI ≥30 kg/m2.
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diScuSSioN
In the present study, performed in a large population-based cohort of almost 60,000 
individuals, we investigated the relationship between smoking and the individual 
components of metabolic syndrome, and the association between smoking and levels 
of apolipoproteins and estimated lipoprotein particle size. Such a comprehensive and 
large-scale analysis has not been performed to date. We demonstrated that in both 
men and women smoking is associated with a greater prevalence of MetS, irrespective 
of their BMI. The largest differences between current smokers and non-smokers were 
observed in the levels of HDL-C and triglycerides, and, to a lesser extent, in waist circum-
ference. While there were no consistent associations between smoking status and either 
blood pressure or fasting blood glucose levels, there was a dose-dependent relationship 
between the amount of tobacco smoked and decreased HDL-C levels and increased 
triglyceride levels. We also found a clear dose-dependent association between the 
amount of tobacco smoked and reduced ratios of HDL-C/apoA1 and LDL-C/apoB. To our 
knowledge, we are the first to explore these associations between smoking and levels 
of apolipoproteins and lipoprotein particle size in such a large cohort of individuals, 
with rigorously standardized physical and laboratory measurements, while taking into 
account both sex and BMI levels.
Our analysis revealed that in both men and women the prevalence of MetS was 
higher in current smokers in each BMI group, than in the non-smokers within that BMI 
group. Several earlier small-scale studies have reported smoking to be associated with 
higher prevalence of MetS [24-27]. The positive dose-response relationship between 
the amount of tobacco smoked and the prevalence of MetS that we observed is also 
consistent with previous studies [10,13,26,28]. However, when BMI was included in our 
analysis, the odds ratio for having MetS was higher among normal weight smoking sub-
jects than those with higher BMI (Figure 3). This is probably related to the initial lower 
risk of subjects in this BMI group. Since previous studies have shown an excess of visceral 
fat to be a major contributor to metabolic abnormalities, overweight and obesity are 
known to be highly associated with MetS [29], with already a high prevalence of MetS 
observed in the obese non-smokers.
With our approach we have been able to calculate precisely the effects of smoking 
on the lipid parameters. Our data unequivocally show that despite the fact that obese 
men and women have a lower mean HDL-C than non-obese, the effects of heavy smok-
ing are similar in all three BMI groups, with a consistent 0.10 to 0.14 mmol/l lower HDL-C 
for smoking men, and 0.15 to 0.21 mmol/l lower HDL-C in smoking women, in all three 
BMI groups (Table 4). The fact that we found current smoking to be mainly associated 
with lower levels of HDL-C, higher levels of triglycerides and larger waist circumference 
than the non-smoking status is consistent with earlier cross-sectional studies [28,30]. 
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This observation of a dose-dependent relationship between the daily amount of to-
bacco smoked and lower HDL-C and higher triglycerides confirms the results of previous 
reports [13,31-33]. In our study, the magnitude of the effects of tobacco usage on HDL-C 
varied between 0.04 for light smoking in men, and 0.21 mmol/l for heavy smoking in 
normal weight women. The study by Chen et al., comprising 1,164 men, reported a simi-
lar dose-response relationship with the largest effect on HDL-C and triglycerides seen 
in those who smoked more than 40 cigarettes per day [13]. Ishizaka et al. also reported 
a dose-response association between the number of cigarettes per day and prevalence 
of MetS in a cohort of 5,033 individuals, although they did not examine the influence 
of the amount of tobacco smoked on the individual MetS components [33]. A recent 
review summarized the effects of smoking cessation on HDL-C levels: within a few weeks 
after stopping smoking, HDL-C levels start to increase, resulting in an overall increase 
of 0.2 mmol/l [34]. Taken together, these and our data support the causal relationship 
between smoking and low HDL-C levels.
There are indications that current smoking is associated with increased abdominal 
obesity [35]. In our study, although current smokers had a greater waist circumference 
than non-smokers, these differences were rather small. We also observed a consistent in-
crease in the waist circumference with an increase in tobacco smoked in normal weight 
and overweight men, as well as in normal weight and obese women. Larger effects 
were especially seen among obese women, where the increase in waist circumference 
was 2.2 cm for moderate smokers and 6.4 cm for heavy smokers. One of the possible 
mechanisms that might explain these observations is a direct effect of smoking on 
cortisol production [12,36]. Indeed, it was demonstrated more than three decades ago 
that smokers have higher fasting plasma cortisol levels than non-smokers [37,38]. The 
increase in cortisol production leads to accumulation of abdominal fat [39], which, in 
turn, increases waist circumference.
Although some studies have indicated that smoking is related to reduced insulin 
sensitivity and the development of insulin resistance [12,40] and type 2 diabetes [41,42], 
in our population there was no consistent association between smoking and fasting 
blood glucose. This confirms the results obtained in other studies [13,30,43]. Ishizaka 
et al. found a higher prevalence of elevated blood glucose in smoking men, but not in 
women [33]. Such discrepancy in the results may be due to the different cut-off values 
for elevated fasting glucose used in the present study (5.6 mmol/l) and that of Ishizaka 
et al. (6.1 mmol/l) [33].
While it is well established that acute smoking may cause a rise in blood pressure 
[44,45], in the chronic situation smokers’ blood pressure is similar to or even lower than 
that of non-smokers [33,44,46], although Primatesta et al. found higher blood pres-
sure in male smokers older than 45 years compared to never smokers [47]. We found 
no association between smoking and blood pressure in any of the three BMI classes, 
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even after correction for the use of blood pressure-lowering medication. In addition, 
we found similar blood pressure in smokers aged 45 and higher versus non-smokers 
(data not shown). Nevertheless, some studies have suggested that smoking may be a 
risk factor for developing hypertension [48] or for an increase in blood pressure during 
exercise [49], although in the latter study smoking cessation did not lead to reduced 
blood pressure. Weight changes after smoking cessation have been suggested to be 
involved in this paradox [48].
One of the new findings of our study is the association between smoking and altera-
tions in levels of apolipoproteins and in the size of lipoprotein particles. Until now, only 
a limited number of studies have investigated the relationship between smoking and 
the levels of apoA1 and apoB, usually involving a small number of participants such 
as, for example, young adults [18,50], middle-aged men [19,51], or postmenopausal 
women [20]. In addition, few studies have assessed the effects of smoking on lipoprotein 
particle size. In the Framingham study, smoking was associated with higher levels of 
small LDL particles [52]. However, apoA1 and apoB measurement and standardization 
have considerably improved in the last decade, both because of the appearance of a 
legal and regulatory framework (the In Vitro Diagnostics (IVD)-directive 98/79/EC and 
the institution of the Joint Committee on Traceability in Laboratory Medicine (JCTLM)), 
technical improvements of equipment, and the availability of international reference 
materials [21]. An additional milestone was the preparation, evaluation and introduc-
tion of value-assigned reference materials for monitoring trueness of apolipoprotein 
test results [22]. ApoA1 is the main protein component of HDL-C particles, and higher 
levels of apoA1 are associated with lower risk of CVD [53]. We observed that in current 
smokers plasma apoA1 levels were lower than in non-smokers. In addition, smoking was 
associated with lower HDL-C/apoA1 ratio, which is a strong indication of smaller HDL 
particle size. Such alterations of the HDL particle have been negatively associated with 
heart disease [54,55]. While apoA1 is protective, apoB, the main protein component of 
LDL particles, reflects the atherogenic potential of LDL, and higher levels of apoB are 
associated with an increased risk of CVD [53]. The fact that we found higher apoB levels 
and lower LDL-C/apoB ratios in current smokers than in non-smokers, indicates the 
presence of increased numbers of small, more dense LDL particles. Such particles have 
been found to increase the risk not only of atherosclerosis [56,57], but also of coronary 
artery disease [58] and fatal myocardial infarction [59]. Furthermore, in a 3-year follow-
up study among Korean men without MetS, a low LDL-C/apoB ratio was independently 
associated with development of MetS [60]. Taken together with our findings, the Korean 
study supports the conclusion that the presence of increased amounts of small, dense 
LDL particles can be considered both a risk factor for future cardiovascular disease and 
an early feature of metabolic syndrome.
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Our study has several major strengths. Considering the number of participants 
recruited from the general population (N >59,000), this is the largest study reporting 
these results. Our large dataset also enabled to carefully calculate effect sizes, and to 
perform sufficiently powered subgroup analyses, in subjects of both sexes and in those 
with normal body weight, overweight, and obesity, which to our knowledge has never 
been performed before. All participants to the LifeLines Cohort Study have been well 
characterized, with rigorously standardized blood pressure and anthropometric mea-
surements. In addition, all laboratory measurements of lipids and apolipoproteins have 
been carried out over a period of 5 years in fresh serum samples, in the same certified 
laboratory, with the same equipment, and the same rigorous quality assessment and 
control. This unprecedented sample size also provided us with sufficient statistical 
power to investigate contradictory associations reported previously.
There are also some limitations to our study. Firstly, since smoking status was based 
on self-administered questionnaires, we cannot exclude the possibility that misreport-
ing led to some individuals being misclassified with regard to their current smoking 
status. Considering the large number of participants, we believe that misclassification 
has only very limited influence on the results obtained, and earlier studies also reported 
low misclassification rate of smoking status [61]. We should point out that we were un-
able to identify individuals who had never smoked, nor could we fully take into account 
the duration of smoking. Secondly, apart from age we could not adjust for other possibly 
relevant risk factors that influence levels of HDL cholesterol and triglycerides, such as 
nutrition and alcohol consumption. As data collection for the LifeLines Cohort Study 
is still ongoing, we hope to be able to investigate the effects of such factors on MetS in 
the future.
coNcluSioNS
In this very large study in individuals of western European descent, smoking was associ-
ated with an increased risk of MetS. This increased risk was observed in all BMI classes. 
The elevated risk of having MetS was mainly related to lower HDL cholesterol, higher 
triglycerides and larger waist circumference. We also found that smoking was associated 
with unfavorable changes in the levels of apoA1 and apoB and in estimated HDL and 
LDL particle size, thereby providing a new pathophysiological mechanism linking smok-
ing to increased risk of cardiovascular disease.
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